Weight loss drugs linked to increased risk of hair loss, researchers say
Researchers found GLP-1 drugs were linked to a 37% higher alopecia risk than SGLT-2 inhibitors and a 68% higher risk than DPP-4 inhibitors.
- On Wednesday, a study published in The BMJ linked GLP-1 drugs—including Wegovy, Ozempic, Mounjaro, and Zepbound—to a higher risk of alopecia in type 2 diabetes patients compared to SGLT-2 and DPP-4 inhibitors.
- Researchers at the University of Pennsylvania Health System reported a 37% higher risk of hair loss for GLP-1 users compared to SGLT-2 inhibitors, and a 68% higher risk versus DPP-4 inhibitors.
- While the risk remains low at roughly 7 people per 1,000 annually, the team cited "reduced caloric intake" as the "most likely mechanism" disrupting hair growth cycles.
- The US Food and Drug Administration is evaluating the safety signal, while the UK Medicines and Healthcare products Regulatory Agency has received 399 reports of hair loss linked to tirzepatide in 2026.
- Separate research suggests hair loss is often reversible, though experts advise patients to weigh this potential adverse effect against the "substantial and well-established benefits" of GLP-1 therapies for obesity and diabetes.
64 Articles
64 Articles
Weight loss drugs linked to increased risk of hair loss
Weight loss drugs such as Mounjaro, Ozempic and Wegovy are linked to an increased risk of hair loss, according to researchers. المصدر: skynews technology The post Weight loss drugs linked to increased risk of hair loss appeared first on khbrknews.
Alopecia typically occurs about a year after starting weight loss treatment, as research suggests.
Ozempic and Mounjaro linked to a surprising hair loss risk
A large study suggests that GLP-1 drugs including Ozempic and Mounjaro may slightly increase the risk of hair loss in people with type 2 diabetes. Compared with two other common classes of diabetes medications, GLP-1 users had a significantly higher rate of alopecia, though the absolute risk was still low. The hair loss was mainly non-scarring, which means it may be reversible.
Coverage Details
Bias Distribution
- 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
